Aurobindo Pharma Q1 FY27 Revenue Up 16% to ₹9,150 Cr

Consolidated Revenue: ₹9,150 crores, representing 16% year-on-year growth
Formulation Business Revenue: ₹8,101 crores (17% YoY growth), contributing 89% of total revenue
API Business Revenue: ₹1,049 crores (11% of total revenue)
Operating EBITDA: ₹1,924 crores with margin of 21% (includes one-time impact of ₹43 crores for loss on derecognition of leased residuals)
Gross Margin: 60.4% compared to 58.8% in Q1 FY26
Gross Contribution: ₹5,523 crores
R&D Expenses: ₹344 crores (4% of revenues)
Net CapEx: $78 million for the quarter
Profit After Tax: ₹1,032 crores
Net Cash Position: $42 million after $85 million buyback and $247 million Lannett acquisition payments
Average Finance Cost: 4.8% (down from 5% previous quarter)
Net Effective Tax Rate: 31.9% (expected to normalize to 28-29% by year-end)

US Market: Revenue of ₹3,770 crores ($399 million), representing 8.1% YoY growth
European Market: Revenue of €267 million, delivering 11% YoY growth in constant currency terms
Growth Markets: Revenue of ₹1,063 crores ($113 million), showing 38% YoY growth
ARV Formulations: Stable at $35 million for the quarter

Product Launches: 10 new products launched in US market during quarter
Regulatory Filings: 9 ANDAs filed and 10 final approvals received
Lannett Acquisition: Successfully completed following FTC approval, strengthening US platform in complex generics and controlled substances
China OSD Facility: Production doubled over past 12 months, now supplying to Europe and US markets
Biosimilar Progress: ANVISA GMP certification secured for drug substance and drug product facilities

Lannett integration progressing with planned product transfers to utilize idle capacity (currently at 40% utilization)
Advair launch planned for August 2026 after inventory build-up
Controlled substances portfolio showing growth within quota limitations
SGA synergies and procurement benefits expected from Lannett integration

Achieved 20% EBITDA margin
Expecting double-digit growth for FY27 driven by new launches including loss of exclusivity products
Antibiotic season expected to strengthen in upcoming months (September-October onwards)

US Filings: Three biosimilar filings planned for 2026, targeting at least three products in US by 2030
European Progress: Four approvals received, guidance of 7-8 products in EU/UK/Canada by 2028-29
Recent Filings: Denosumab (BP-16) filed with CHMP; Omalizumab filing on track for Q3 with European Medicines Agency
TheraNym Biologics (CMO): Unit 1 qualification activities scheduled for November 2026, validation batches in 2027, steady revenue stream expected from 2028
Revenue Guidance: $150-200 million expected from TheraNym Unit 1 and 2 by 2032 with EBITDA margins of 35-50%

Production capacity of 800-900 tonnes per month
Supplying to Indian market and external parties
PLI incentive application filed, expected payment in September or March
Working toward cost competitiveness irrespective of MIP (Minimum Import Price) benefits

A1 Biochem Acquisition: Recently acquired CRO business with ₹100 crores revenue, potential to scale 3-5x in 3-5 years
China Formulation Facility: Current capacity of 2+ billion tablets, production doubled in quarter, target to exceed 2 billion by year-end/mid-next year
Canada Market: Developing captive supply strategy similar to European model

Management reiterated FY27 guidance: